Enteric Disease Testing Market Insights, Regional Developments And Demand

 The global enteric disease testing market size was valued at USD 3.81 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 2.7% from 2023 to 2030. Vital drivers of this market include technological advancements and supportive government funding in emerging economies. Furthermore, growing global demand for early diagnostics is expected to enhance the applicability of the market, fueling its growth.

Gather more insights about the market drivers, restrains and growth of the Enteric Disease Testing Market

Throughout the COVID-19 pandemic, there was an increasing focus on viral and bacterial infections, leading individuals to prioritize the consumption of home-cooked and hygienic food to minimize the risk of infection. Therefore, there was a decrease in the incidence of enteric diseases and a subsequent decline in the demand for enteric disease testing in 2020 and 2021. Additionally, COVID-19 testing had top priority during the pandemic, surpassing testing for other infectious diseases, due to which the demand for enteric disease testing products experienced a negative impact, thereby impeding market growth.

In regions such as Asia, Africa, and Latin America, the prevalence of enteric infections, including salmonella, campylobacter, escherichia coli, and norovirus, remains significantly high. According to the National Library of Medicine, as of 2018, a case fatality rate of 1% is observed in enteric fever cases in the Asia and Africa regions. Consequently, there is an increasing demand for enteric disease testing to enable accurate and timely diagnoses. Moreover, there is increasing awareness among individuals, healthcare providers, and government entities regarding the importance of early detection and effective management of enteric diseases. As a result, various organizations and government bodies are undertaking initiatives to enhance awareness, implement screening programs, and advocate for the utilization of diagnostic tests, thereby stimulating market growth.

The traditional diagnostic process of enteric diseases was based on the culture method which demanded skilled staff and was a time-consuming procedure. The development of molecular diagnostics and other diagnostic technologies revolutionized the enteric disease testing market over the last decade. The increasing mortality rate due to these conditions and the cost efficiency of technologically advanced diagnostic systems are expected to drive the demand for early diagnosis of these conditions.

Initial symptoms associated with enteric diseases include abdominal cramps, vomiting, nausea, and anorexia, which can progress to severe conditions characterized by substantial fluid and nutrient loss from the body. The vulnerability of pediatric and geriatric age groups to these diseases is sensitive due to their weakened immune systems. According to the Bill and Melinda Gates Foundation, annually, approximately 500,000 young children under the age of 5 succumb to enteric and diarrheal diseases, predominantly in developing nations. Furthermore, an estimated 25,000 children annually lose their lives to enteric fever, primarily affecting regions lacking access to safe water and adequate sanitation facilities.

The mild initial symptoms of enteric diseases are sometimes overlooked, which poses a significant constraint to the market. These diseases have emerged as a leading cause of morbidity and mortality globally, particularly in developing countries with inadequate drainage and sanitation infrastructure. In terms of incidence and epidemiology, it is estimated that developing nations contribute to more than 85% of the total enteric infection cases.

Rising incidence of enteric diseases and the cost-efficiency of technologically advanced diagnostic systems are expected to drive demand for the early diagnosis of enteric disease. For instance, according to the Centers for Disease Control and Prevention, salmonella bacteria cause approximately 1.35 million infections, around 26,500 hospitalizations, and about 420 deaths every year in the U.S. Increasing incidence of enteric conditions in developing economies along with a lack of adequate laboratory settings and limited awareness is expected to provide a largely untapped market. According to the Foundation Merieux, enteric diseases are the second leading cause of death among children under 5 years in Asian and African countries. In addition, 90% of deaths caused by diarrhea are due to a lack of access to safe drinking water and basic sanitation facilities. Furthermore, 90% of deaths due to typhoid occur in Asia. As of 2021, there are an estimated 11 to 21 million typhoid fever cases and 128,000 to 161,000 deaths in south Asian countries every year. Thus, the increasing prevalence of enteric disease and poor sanitation facilities in developing countries provides a largely untapped market.

Molecular diagnostics are used in various areas of microbiology, which include strain identification and isolation of enteric pathogens. Disease-causing microorganisms are also studied using different molecular diagnostics techniques. The application of molecular diagnostics in microbiology is expected to increase due to the introduction of technologically advanced instruments with improved accuracy levels. Clinical laboratories are adopting molecular diagnostics as a part of laboratory automation. Currently, polymerase chain reaction (PCR), implicit association test (IAT), and gene chip are the most widely used molecular diagnostic tests for infectious diseases. Thus, the rising adoption of molecular diagnostics in the detection of enteric diseases is expected to drive the enteric diseases market over the forecast period.

Technological advancement is another key factor accelerating market growth. Technological advancements such as gastrointestinal panel tests are used for the identification and qualitative detection of multiple parasitic, bacterial, and viral nucleic acids in individuals with signs and symptoms of gastroenteritis or infectious colitis. The tests are performed on saliva and stool samples to generate rapid results for 15 pathogens in 6 hours. It is also used for testing the inherited food sensitivities/allergies to organisms such as Toxoplasma gondii and Entamoeba histolytica. This test has been approved by the U.S. FDA. Market players undergoing clinical studies to develop a new diagnostic test with high accuracy and high-performance delivery is anticipated to drive the market. For instance,in November 2019, the XTAG Gastrointestinal (GPP) test was approved by the Food and Drug Administration (FDA). XTAG is a multiplexed nucleic acid test designed to detect multiple viral, parasitic, and bacterial nuclei in stool samples simultaneously.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global alginate dressing market size was valued at USD 938.3 million in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. The rising incidence of chronic and acute wounds is the major factor driving the industry.

• The Asia Pacific disposable endoscopes market size was valued at USD 705.6 million in 2023 and is projected to grow at a CAGR of 18.3% from 2024 to 2030. Disposable endoscopes are vital for reducing cross-contamination and improving patient safety during medical procedures.

Enteric Disease Testing Market Segmentation

Grand View Research has segmented the global enteric disease testing market on the basis of disease type, and region:

Enteric Disease Testing Disease Type Outlook (Revenue, USD Million, 2018 - 2030)
• Bacterial Enteric Disease
• Viral Enteric Disease
o Rotavirus
o Norovirus
• Parasitic Enteric Disease

Enteric Disease Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Norway
o Denmark
• Asia Pacific
o Japan
o China
o India
o Australia
o Thailand
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa
o Saudi Arabia
o South Africa
o UAE
o Kuwait

Order a free sample PDF of the Enteric Disease Testing Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• Abbott
• BD
• Biomerica
• BIOMÉRIEUX
• Bio-Rad Laboratories, Inc.
• Cepheid
• Coris BioConcept
• DiaSorin S.p.A.
• Meridian Bioscience
• Quest Diagnostics Incorporated

Defibrillators Market Growth Report And The Role Of Healthcare Infrastructure

 The global defibrillators market size was estimated at USD 7.32 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2030. Increasing product development activities, rising incidence of sudden cardiac arrest, growing awareness among the general public, and supportive initiatives by governments & healthcare organizations are some of the key factors fueling industry growth. In May 2021, Rapid Response Revival Research Ltd.-an Australian company-received a CE mark for its CellAED, the world’s first personal automated external defibrillator (AED) for home use. This supported the company’s growth strategy.

Gather more insights about the market drivers, restrains and growth of the Defibrillators Market

The COVID-19 pandemic adversely impacted the industry, particularly the International Classification of Diseases (ICDs) market, with dampened demand and sales during 2020. The sales improved as the hospitals resumed elective surgeries. However, the progression of COVID-19 in several key markets continued to create uncertainty during the year. Abbott, for instance, reported improvement in its hospital-based businesses during Q2 and Q3 2020. However, the improving trends flattened or were negatively impacted during Q4 2020 due to a sudden increase in COVID-19 cases and hospitalizations in many countries. Nihon Kohden, on the other hand, reported strong sales growth of defibrillators in 2020, despite inhibited sales activity due to the pandemic.

Increasing geriatric population globally and technological advancements are other key factors that are projected to significantly impact market growth. The older population, particularly those aged between 65 years and above, is more vulnerable to chronic diseases, such as cardiovascular diseases (CVDs), which often require the placement of defibrillators to restore a normal heart rhythm by delivering an electric shock to the heart. For instance, in November 2022, the article "Senior Population Statistics: A Portrait of Aging Americans" reported that around 54.1 million (16.3%) individuals in the U.S. are aged 65 years or above. Thus, the growing geriatric population contributes to the increasing product demand.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global neuromodulation devices market size was valued at USD 5.31 billion in 2023 and is projected to grow at a CAGR of 10.2% from 2024 to 2030. The rising government funding for R&D activities in these devices, the increasing prevalence of neurological disorders, and technological advancements are driving the market growth.

• The global subdermal contraceptive implants market size was valued at USD 1.05 billion in 2023 and is projected to grow at a CAGR of 7.5% from 2024 to 2030. The driving factors of the growth include rising demand for reliable contraceptives, unintended pregnancies, and increasing awareness of sexual health and family planning.

Defibrillators Market Segmentation

Grand View Research has segmented the global defibrillators market on the basis of product, end-use, and region:

Defibrillators Product Outlook (Revenue, USD Million, 2018 - 2030)
• Implantable Cardioverter Defibrillators (ICD)
o S-ICD
o T-ICD
o Single Chamber
o Dual Chamber
o CRT-D
• External Defibrillators (ED)
o Manual ED
o Automated ED
o Wearable Cardioverter Defibrillators

Defibrillators End-use Outlook (Revenue, USD Million, 2018 - 2030)
o Hospital
o Pre-hospital
o Public Access Market
o Alternate Care Market
o Home Healthcare

Defibrillators Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o India
o Japan
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• MEA
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Order a free sample PDF of the Defibrillators Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• Medtronic
• Abbott
• Boston Scientific Corporation
• BIOTRONIK SE & Co. KG
• MicroPort Scientific Corporation
• Koninklijke Philips N.V.
• Stryker
• ZOLL Medical Corporation (Asahi Kasei)
• Nihon Kohden Corporation
• Schiller AG

Inflammatory Bowel Disease Treatment Market Dynamics, Understanding Patient Needs And Preferences

The global inflammatory bowel disease treatment market size was estimated at USD 20.74 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. The rising prevalence of ulcerative colitis and Crohn's disease across the globe and increasing approval of novel therapeutics are anticipated to drive the market during the forecast period. Moreover, an increase in the adoption of biological drugs and a surge in government initiatives to improve healthcare services for patients with inflammatory bowel disease (IBD), as these patients are more susceptible to acquiring infections owing to immunosuppressive therapies, further support the market expansion.

The rising prevalence of ulcerative colitis and Crohn's disease is anticipated to fuel the growth of the inflammatory bowel disease treatment market. According to EFCCA, around 10 million people are living with inflammatory bowel diseases worldwide, and the incidence of the disease is expected to increase over the forecast period. Similarly, a study published by the Crohn's & Colitis Foundation in July 2023 estimated that 721 per 100,000 Americans were diagnosed with inflammatory bowel disease. Moreover, in September 2023, NCBI published that more than 320,000 people in Canada will have IBD in 2023, and it is expected to reach 470,000 IBD patients by 2035 in the country.

The upcoming product launches and a strong product pipeline will drive market growth. For instance, in April 2023, AbbVie Inc. received the European Commission (EC) approval for Rinvoq (upadacitinib) to treat moderate to severe Crohn's disease in adult patients. Current therapies focus on reducing inflammation, risks of complications, and long-term remission. Moreover, hospitals & healthcare institutes are working closely with pharmaceutical companies to conduct clinical trials and ensure the safety of patients. Such initiatives are expected to increase research activities and develop a novel treatment for IBD.

The leading participants in the IBD treatment market emphasize adopting advanced technologies like AI for drug discovery and offering new treatments for Crohn's disease and ulcerative colitis. For instance, in December 2023, Insilico Medicine dosed the first patients with its ISM5411, an investigational IBD drug candidate designed using generative artificial intelligence. Moreover, leading companies and tech innovators are collaborating to leverage each other's technologies and competencies to innovate novel regimens and strengthen their position. For instance, in May 2021, CytoReason, an Israel-based tech company, announced a partnership with Ferring Pharmaceuticals to accelerate the drug development process and innovate novel therapeutics for IBD using AI technology.

Key Companies profiled:
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Biogen
• Novartis AG
• Lilly
• UCB S.A.
• CELLTRION INC.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global schizophrenia drugs market size was valued at USD 7.90 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. The increasing demand is due to the rising prevalence of schizophrenia and other related mental health disorders worldwide.

• The global artemisinin combination therapy market size was valued at USD 597.2 million in 2023 and is projected to grow at a CAGR of 8.2% from 2024 to 2030. It is attributed to the rising malaria in various regions.

Inflammatory Bowel Disease Treatment Market Segmentation

Grand View Research has segmented the global inflammatory bowel disease treatment market based on type, drug class,route of administration, distribution channel, and region:

Inflammatory Bowel Disease Treatment Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Crohn's Disease
• Ulcerative Colitis

Inflammatory Bowel Disease Treatment Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
• Aminosalicylates
• Corticosteroids
• TNF inhibitors
• IL inhibitors
• Anti-integrin
• JAK inhibitors
• Others

Inflammatory Bowel Disease Treatment Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
• Oral
• Injectable

Inflammatory Bowel Disease Treatment Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Inflammatory Bowel Disease Treatment Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o Germany
o UK
o Spain
o France
o Italy
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
o Singapore
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Order a free sample PDF of the Inflammatory Bowel Disease Treatment Market Intelligence Study, published by Grand View Research.

Recent Developments

• In May 2024, Johnson and Johnson Services Inc., announced the first phase 3 results for Tremfya’s Crohn’s disease program. The data from phase 3 trial demonstrated that Tremfya is superior to Stelara in all the endoscopic patients in the trial pool.

• In April 2024, Takeda Pharmaceutical Company Limited received FDA approval for subcutaneous administration of Entyvio post-induction therapy with IV Entyvio. The drugs are used to treat patients with severely active Crohn’s Disease.

• In October 2023, Johnson & Johnson Services, Inc. announced the data from a phase 3 clinical trial of Tremfya (guselkumab), studying the safety and efficacy of the drug for active ulcerative colitis. The study showed a 77% overall clinical response rate and early symptom improvement in UC patients.

• In June 2023, Lilly's Omvoh (mirikizumab) received market authorization from UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of ulcerative colitis.

• In February 2023, AbbVie announced that the UK's MHRA approved RINVOQ, a JAK inhibitor, for treating patients with moderate to severe Crohn's disease who had an inadequate response to conventional therapy.

• In January 2023, Inotrem, a clinical-stage biotechnology company, received funding from the Crohn's & Colitis Foundation to help develop novel therapeutic approaches in Crohn's disease and ulcerative colitis.

Corporate Wellness Market: Addressing Employee Burnout And Engagement

Corporate Wellness Industry Overview

The global corporate wellness market size was valued at USD 53.0 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 4.47% from 2023 to 2030. Many businesses and enterprises in various industry verticals have started implementing health programs for their employees, which will boost the market demand. Health programs at the workplace help companies in augmenting productivity while reducing overall operational costs. Rising awareness regarding employee health and well-being is expected to drive the market for corporate wellness.

Gather more insights about the market drivers, restrains and growth of the Corporate Wellness Market

Corporate wellness programs include a set of policies, programs, and benefits addressing multiple risk factors and conditions and influencing both employees and the overall organization. According to the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), in the U.S., corporate programs promoting well-being and health, and providing disease prevention plans can potentially influence more than 150 million employees reducing the cost of healthcare significantly.

Employees are encouraged to adopt a healthier lifestyle and help companies to enhance productivity and reduce costs, by ultimately improving employee well-being. The total costs related to lost productivity due to absenteeism related to illnesses are expected to cross USD 150 billion in the coming years. The increase in the overweight and obese population results in increased insurance costs, which places a financial strain on companies.

Additionally, market growth is being driven by an increase in the prevalence and early onset of chronic diseases, as well as a decrease in employee healthcare costs. Today's work culture means that the majority of individuals do not have enough time to engage in mental and physical activities after work or during their free time, resulting in health problems. Globally, chronic diseases are a significant threat, since the prevalence of many of these disorders continues to rise. For example, the World Health Organization (WHO) estimates that cancer will claim around 10 million lives by 2020.

Furthermore, according to the American Cancer Society's 2021 statistics, the global burden of cancer is anticipated to rise to 16.3 million cancer deaths and 27.5 million new cases by 2040. Similarly, heart diseases, obesity and diabetes are some of the chronic diseases that have afflicted many countries around the world as a result of an unhealthy and sedentary lifestyle, including many industrialized nations. As a result, the prevalence of numerous chronic diseases is increasing. These diseases, however, are avoidable. As a result, holistic approaches to workplace wellness programmes are in high demand to educate employees about the importance of building healthy habits and the advantages of sticking to fitness goals.

The COVID-19 pandemic has had a significant influence on employees' mental health. Following its inception, it resulted in the work-from-home transition, which caused significant stress among employees due to a sense of isolation. Due to the COVID-19 epidemic, businesses have discovered ways to physically protect and prioritize their employees by giving technical support to aid in the adoption of new leave policies. Employers' priorities have switched to preventive and constructive management, which includes assisting employees in adapting to new requirements.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global bowel management systems market size was valued at USD 1.73 billion in 2023 and is projected to grow at a CAGR of 3.4% from 2024 to 2030. This growth is attributed to the increasing prevalence of bowel-related disorders and conditions, such as inflammatory bowel disease, fecal incontinence, and colorectal cancer.

• The Kingdom of Saudi Arabia air ambulance market size was valued at USD 222.7 million in 2023 and is projected to grow at a CAGR of 6.1% from 2024 to 2030. The driving factors of the growth include rising incidences of chronic diseases, growing demand for air travel for medical reasons, and an increase in healthcare expenditures.

Corporate Wellness Market Segmentation

Grand View Research has segmented the global corporate wellness market based on service, end-use, category, delivery model, and region:

Corporate Wellness Service Outlook (Revenue, USD Million, 2016 - 2030)
• Health Risk Assessment
• Fitness
• Smoking Cessation
• Health Screening
• Nutrition & Weight Management
• Stress Management
• Others

Corporate Wellness End-Use Outlook (Revenue, USD Million, 2016 - 2030)
• Small Scale Organizations
• Medium Scale Organizations
• Large Scale Organizations

Corporate Wellness Category Outlook (Revenue, USD Million, 2016 - 2030)
• Fitness & Nutrition Consultants
• Psychological Therapists
• Organizations/Employers

Corporate Wellness Delivery Model Outlook (Revenue, USD Million, 2016 - 2030)
• Onsite
• Offsite

Corporate Wellness Regional Outlook (Revenue, USD Million, 2016 - 2030)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Netherlands
o Switzerland
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa (MEA)
o South Africa
o Saudi Arabia
o UAE

Order a free sample PDF of the Corporate Wellness Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• ComPsych
• Wellness Corporate Solutions
• Virgin Pulse
• EXOS
• Marino Wellness
• Privia Health
• Vitality
• Wellsource, Inc.
• Central Corporate Wellness
• Truworth Wellness
• SOL Wellness

Investment Opportunities In The Antifungal Drugs Market: A Guide For Stakeholders

 The global antifungal drugs market size was estimated at USD 15.8 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2024 to 2030. The growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors propelling the market. Fungal infections encompass both systemic and superficial infections including infections of the skin, eye, mouth, and vagina. Antifungal products with fungicidal activity are mostly used to treat a wide array of diseases, such as athlete's foot, ringworm, and fungal meningitis, caused by fungal agents. Mounting cases of hospital-acquired or nosocomial infections and infectious diseases are poised to propel the growth of the market during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Antifungal Drugs Market

Fungal diseases are a public health problem as they can affect any individual. However, there is severe threat of fungal infections to people with weak immune responses such as patients with AIDS. There is a high possibility of development of opportunistic fungal infections in these patients. According to statistics published by the CDC, every year, nearly 152,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 112,000 deaths per year globally. Most of the deaths are reported in sub-Saharan Africa, as the prevalence of HIV/AIDS is more in these countries. This indicates a potential unmet need for highly potent antifungal drugs.

Increase in awareness levels is expected to improve the diagnosis rate of fungal infections, which, in turn, is projected to drive the adoption rate of the treatment drugs. In September 2022, Fungal Disease Awareness Week was celebrated by CDC to highlight the importance of antifungal treatments, reducing resistance to antifungal drugs, and recognizing fungal infections at an early stage to reduce mortality rate. These initiatives are being conducted by authorities to improve the level of awareness. Organizations such as Aspergillosis Trust are working toward increasing the awareness levels about aspergillosis while platforms such as aspergillosis.org have introduced World Aspergillosis Day and raised funds in alliance with Fungal Infection Trust for patients.

Recent Developments

• In December 2023, Astellas Pharma received FDA approval for Cresemba, an antifungal drug, to treat invasive aspergillosis (IA) and invasive mucormycosis (IM) in children.

• In November 2023, Basilea Pharmaceutica acquires rights to fosmanogepix, a broad-spectrum antifungal, through an agreement with Amplyx Pharmaceuticals. The transformative move strengthens Basilea's clinical antifungal pipeline, with plans for phase 3 studies.

• In October 2023, Basilea Pharmaceutica acquires GR-2397, a clinical-stage antifungal compound, from Gravitas Therapeutics. Rebranded as BAL2062, it targets invasive mold infections, completing a phase 1 study. Basilea plans preclinical profiling, targeting phase 2 by H1 2025. The upfront payment is USD 2 million.

 

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global schizophrenia drugs market size was valued at USD 7.90 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. The increasing demand is due to the rising prevalence of schizophrenia and other related mental health disorders worldwide.

• The global artemisinin combination therapy market size was valued at USD 597.2 million in 2023 and is projected to grow at a CAGR of 8.2% from 2024 to 2030. It is attributed to the rising malaria in various regions. Malaria remains a significant public health challenge, with millions of cases reported annually.

Antifungal Drugs Market Segmentation

Grand View Research has segmented the global antifungal drugs market report based on drug class, indication, dosage form, distribution channel, and region:

Antifungal Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others

Antifungal Drugs Indication Outlook (Revenue, USD Million, 2018 - 2030)
• Dermatophytosis
• Aspergillosis
• Candidiasis
• Others

Antifungal Drugs Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)
• Oral Drugs
• Ointments
• Powders
• Others

Antifungal Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacies
• Retails Pharmacies
• Others

Antifungal Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Denmark
o Norway
o Sweden
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o Saudi Arabia
o UAE
o South Africa
o Kuwait

Order a free sample PDF of the Antifungal Drugs Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• Novartis AG
• Pfizer, Inc.
• Bayer AG
• Sanofi
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Abbott
• Glenmark
• Enzon Pharmaceuticals, Inc.
• Astellas Pharma, Inc.

Key Antifungal Drugs Company Insights

• Pfizer, Inc. is engaged in discovery, development, and manufacture of pharmaceutical products. It has a portfolio of vaccines and medicines. The company operates through two business segments: Essential Health (EH) and Innovative Health (IH).

• Merck & Co., Inc. is a global healthcare company involved in development, discovery, manufacture, and commercialization of prescription, branded, & over-the-counter vaccines, pharmaceuticals, and consumer care products for human & animal healthcare markets

• Enzon Pharmaceuticals, Inc. and Astellas Pharma, Inc. are some of the emerging market participants in the antifungal drugs market.

• Astellas Pharma, Inc. is engaged in import/export, manufacture, and marketing of pharmaceuticals. The company has products in the following segments: oncology, neurology, urology, nephrology, immunology, and women's health treatments.

 

Strategic Developments In The Precision Medicine Market: A Comprehensive Review

 Precision Medicine Industry Overview

The global precision medicine market size was estimated at USD 87.50 billion in 2023 and is projected to grow at a CAGR of 16.3% from 2024 to 2030. The market is expected to grow further due to advancements in genomics, increased demand for personalized treatments, and technological innovations in diagnostics. The rising prevalence of chronic diseases, favorable government initiatives, and increased investment in research are likely to drive the market, aiming to improve patient outcomes through tailored therapeutic approaches.

Gather more insights about the market drivers, restrains and growth of the Precision Medicine Market

Next-generation Sequencing (NGS) has transformed genomics and is instantly reshaping clinical diagnosis & personalized medicine. These technological advancements allow for rapid and cost-effective analysis of extensive genomic data, enabling thorough exploration of disease genetics. In clinical settings, NGS is an effective tool for identifying disease-causing variations and facilitating precise & early detection of genetic disorders. In addition, NGS helps diagnose novel disease-related genes & variations, supporting the development of targeted therapies and personalized treatment approaches. These advantages associated with the technology, which include a better understanding of disease mechanisms and identification of specific molecular markers for disease subtypes, significantly enhance precision medicine, enabling tailored medical interventions based on individual characteristics.

Several oncologists expect that NGS combined with companion diagnostics can play a major role in precision diagnostics & therapeutics, significantly increasing the demand for NGS applications. The NGS companion diagnostics space has been continuously evolving and is highly dynamic. Developments in the regulatory framework for the safety & efficacy of NGS-based laboratory tests and increasing clinical investigation data on disease heterogeneity are expected to propel the demand for personalized medicine over the forecast period. For instance, in February 2021, QIAGEN extended its partnership agreement with Inovio Pharmaceuticals, Inc. to develop companion diagnostics for INOVIO’s VGX-3100. VGX-3100 is a phase III DNA immunotherapy candidate for cervical dysplasia.

In addition, due to the successful launch of companion diagnostics, usage & penetration rates of precision diagnostics and drugs greatly depend upon the level of adoption of their respective companion diagnostic tests. Over 150 companion diagnostic on-label combinations and a wide array of precision medicines are expected to be under clinical trials in the coming seven years. Moreover, the adoption of companion diagnostics is expected to increase post-FDA approval of novel tests. The expected increase in accuracy of testing & development of their analysis systems is likely to positively impact the market for companion diagnostics and precision therapeutics & diagnostics over the forecast period.

The utilization of biomarkers for personalized medicine in cancer therapy is also a key factor driving market growth. Biomarkers are crucial in diagnosing cancer and characterizing its specific subtype. This precision allows healthcare professionals to tailor treatment strategies to the unique genetic and molecular profile of each patient’s cancer, improving diagnostic accuracy.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global pancreatic cancer treatment market was valued at USD 2.87 billion in 2023 and is projected to grow at a CAGR of 13.9% from 2024 to 2030. Factors such as unhealthy lifestyles, alcohol consumption, and obesity have been the primary cause of pancreatic cancer in patients.

• The global smoking cessation and nicotine de-addiction market size was valued at USD 25.46 billion in 2023 and is projected to grow at a CAGR of 10.4% from 2024 to 2030. The factors responsible for the market growth are the increasing prevalence of diseases caused due to smoking products.

Precision Medicine Market Segmentation

Grand View Research has segmented the global precision Medicine market on the basis of application, end-use, and region:

Precision Medicine Application Outlook (Revenue, USD Million; 2018 - 2030)
• Diagnostics
o Genetic Tests
o Direct to Consumer Tests
o Esoteric Tests
o Others
• Therapeutics
o Pharmaceuticals
o Oncology
o Respiratory Diseases
o Skin Diseases
o CNS Disorders
o Immunology
o Genetic Diseases
o Others
o Medical Devices
o Others

Precision Medicine End-use Outlook (Revenue, USD Million; 2018 - 2030)
• Home Care
• Hospitals
• Clinical Laboratories
• Others

Precision Medicine Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o Kuwait
o UAE

Order a free sample PDF of the Precision Medicine Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• F. Hoffmann-La Roche Ltd.-(Foundation Medicine)
• Siemens
• Janssen Global Services, LLC
• Illumina, Inc.
• Quest Diagnostics Incorporated
• 23andMe, Inc.
• NeoDiagnostix
• Myriad Genetics
• Medtronic
• GE Healthcare
• Abbott
• QIAGEN

Recent Developments

• In May 2024, Atara filed a Biologics License Application (BLA) with the U.S. FDA for tabelecleucel (tab-cel). It is proposed as a standalone treatment for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) in adults and children aged 2 years and above who have undergone at least one prior therapy. In the case of solid organ transplant recipients, prior therapy typically involves chemotherapy if suitable. Notably, there are currently no FDA-approved treatments available for this specific condition

• In May 2024, Dragonfly Therapeutics, Inc., a biotechnology company dedicated to pioneering new immunotherapies, announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada). This collaboration aims to assess DF9001, Dragonfly's Epidermal Growth Factor Receptor (EGFR) immune engager, alongside Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors expressing EGFR

Biosensors Market Trends, Technology Advancements And End-User Insights

 The global biosensors market size was estimated at USD 28.9 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2030. The demand for biosensors is increasing due to the diversity of medical applications, increasing number of diabetic patients, high demand for compact diagnostic devices, and rapid technological improvement.Accurate early diagnosis of the disease is critical to a positive disease prognosis and patient survival. Demand for disposable, convenient, and economical devices with fast response times has increased dramatically in recent years. The emergence of COVID-19 had a positive impact on the medical device industry. Early symptoms of COVID-19 were scanned using a variety of methods.

Gather more insights about the market drivers, restrains and growth of the Biosensors Market

The biosensors market is on the verge of substantial expansion, driven by noteworthy technological advancements and strategic endeavors by key market players. For instance, in January 2023, Intricon, a developer and manufacturer of medical devices leveraging smart miniaturized electronics, made a significant stride by inaugurating a Biosensors Center of Excellence (CoE). This strategic move highlights Intricon's commitment to integrating its expertise and capabilities in a vertically integrated business unit devoted to introducing biosensor devices to the medical market. Combining technological innovation with a specific focus drives positive growth in the biosensors market.

Nanotechnology-based biosensors are expected to have wide application scope in various industries, such as food analysis, imaging, and microbial activity monitoring. The global market is consolidating due to the growing preference for non-invasive biosensors, rising popularity of medical devices & specialty drugs, and increasing research collaborations & contracts between various manufacturers. For example, Ethicon Endo-Surgery Inc.under contracts administered by Johnson & Johnson Innovation. Another important factor boostingindustry growth is the rising awareness about continuous health monitoring. As a result, the interest of athletes is increasing. Many athletes use Electromyography (EMG) biosensors to keep a close eye on their health and get alerts if something goes wrong.

This early detection can help athletes perform better and stay ahead of their competition. For example, in December 2022, biosensor company Nix launched its first consumer product, Nix Hydration Biosensor. The Hydration Nix Biosensor consists of a Bluetooth-enabled reusable module, a mobile app, and a single-use patch.Despite these considerations, the global market is expected to be constrained by strict regulations and complex cost recovery policies in the global healthcare sector. In addition, existing regulations are slow to adapt to new technologies, hindering product adoption and limiting industry development. The global biosensors market growth is projected to be driven by government programmes focused on the development of proteomics and genomics.

National Information and Communication Technology Australia (NICTA), for example, is projected to expand its data mining, networks, and embedded systems research in this subject. The majority of IT firms are also heavily investing in this sector. Market growth is also driven by investments from major IT companies, such as IBM, Infosys, and TCS. Furthermore, the Chinese government is heavily investing in its computing infrastructure, primarily through the China Grid, which was launched by the Chinese Academy of Sciences, the Ministry of Education, and the China National Grid (CNGrid), supported by the Ministry of Science & Technology. The presence of such beneficial initiatives is projected to boost the market growth.
However, the biosensors market encounters significant challenges, including the necessity for developing compatible single-task tools alongside existing software. The market growth is hindered by a substantial volume of data lacking standardization, impeding seamless integration. There is a crucial demand for user-friendly databases to streamline the analysis of extensive data held by institutions and governments globally, reducing both effort and time.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global non-vascular stents market size was valued at USD 1.63 billion in 2023 and is projected to grow at a CAGR of 4.8% from 2024 to 2030. The growth is fueled by the rising elderly population and the high occurrence of chronic and other illnesses, along with advancements in non-vascular stent technology.

• The global powered surgical instruments market size was valued at USD 2.52 billion in 2023 and is projected to grow at a CAGR of 3.1% from 2024 to 2030. The increasing volume of surgeries globally drives market growth.

Biosensors Market Segmentation

Grand View Research has segmented the biosensors market report on the basis of technology, application, end-user, and region:

Biosensors Technology Outlook (Volume, Unit; Revenue, USD Million, 2018 - 2030)
• Thermal
• Electrochemical
• Piezoelectric
• Optical

Biosensors Application Outlook (Volume, Unit; Revenue, USD Million, 2018 - 2030)
• Medical
o Cholesterol
o Blood Glucose
o Blood Gas Analyzer
o Pregnancy Testing
o Drug Discovery
o Infectious Disease
• Food Toxicity
• Bioreactor
• Agriculture
• Environment
• Others

Biosensors End-user Outlook (Volume, Unit; Revenue, USD Million, 2018 - 2030)
• Home Healthcare Diagnostics
• POC Testing
• Food Industry
• Research Laboratories
• Security and Bio-Defense

Biosensors Regional Outlook (Volume, Unit; Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Belgium
o Switzerland
o The Netherlands
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Indonesia
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
o Colombia
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Turkey
o Kuwait

Order a free sample PDF of the Biosensors Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• Bio-Rad Laboratories Inc.
• Medtronic
• Abbott Laboratories
• Biosensors International Group, Ltd.
• Pinnacle Technologies Inc.
• Ercon, Inc.
• DuPont Biosensor Materials
• Johnson & Johnson
• Koninklijke Philips N.V.
• LifeScan, Inc.
• QTL Biodetection LLC
• Molecular Devices Corp.
• Nova Biomedical
• Molex LLC
• TDK Corp.
• Zimmer & Peacock AS
• Siemens Healthcare

Key Biosensors Company Insights

• Medtronic is a global health solutions company engaged in the development, manufacturing, distribution, and commercialization of device-based medical therapies and services. Organized into four segments—minimally invasive therapies, cardiac & vascular group, restorative therapies, and diabetes group—Medtronic operates globally with a presence in over 370 locations across approximately 160 countries. The company's products find applications in surgical centers, hospitals, home care, and long-term care facilities. Medtronic utilizes direct representatives in the U.S. and employs independent distributors and direct marketing methods in international markets to market its diverse range of medical solutions.

• Abbott is a prominent global healthcare company dedicated to the development, manufacturing, and commercialization of healthcare products worldwide. The company operates through four key segments: pharmaceutical products, diagnostic products, nutritional products, and medical devices. Additionally, Abbott is a leading provider of blood glucose monitoring systems. With a widespread global presence, Abbott conducts operations in over 160 countries, emphasizing its commitment to addressing healthcare needs on a global scale. Notably, Abbott's subsidiary, St. Jude Medical, contributes to the company's diverse portfolio and overall impact in the healthcare industry.

Recent Developments

• In January 2023, Intricon Corporation announced the opening of a Bionsensor Center of Excellence (CoE). The center aims to vertically integrate the company’s business to provide biosensors in medical devices.

Wearable AI Market Trends: The Rise Of Personal Health Monitoring

 Wearable AI Industry Overview

The global wearable AI market size was valued at USD 21.2 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 29.8% from 2023 to 2030. The market is witnessing significant growth due to the exponential rise of emerging technologies, such as artificial intelligence (AI), and 5G smartphone adoption. The increased adoption of smart wearables enabled with AI is due to the advancement of IoT, integration of wireless technology, and the increasing popularity of smartwatches among millennials and Gen Z.

Gather more insights about the market drivers, restrains and growth of the Wearable AI Market

The COVID-19 pandemic had a moderate impact on the market as the supply chain was disrupted during the pandemic and many manufacturers and retailers incurred losses due to the lockdown imposed by the government of different countries. However, the medical wearable AI device segment witnessed a positive impact due to the COVID-19 pandemic owing to the growing demand for telemedicine.

Due to the social distancing norm, medical professionals turned to telemedicine, which allowed them to treat patients virtually without taking the risk of the spreading of the virus. Moreover, researchers studied different data collected from AI wearables to track patients with COVID-19 symptoms. For example, the Oura ring from Oura Health Ltd. was utilized by scientists at the University of California, San Francisco in 2020 to test the physiological data collected by the ring to forecast the onset, progression, and recovery of new COVID-19 cases.

Many key players in the market are targeting gen Z and introducing AI-enabled wearable products, for instance, in June 2022, Noise launched its eyewear, the Noise i1. It offers voice assistance and wireless music streaming by connecting to smartwatches through Bluetooth and attending phone calls. Noise i1 also allows one to play or pause music, answer, or decline calls, and activate the voice assistant on a user's phone.

Various cutting-edge wearable sensory devices with minimally intrusive health monitoring platforms have been developed due to the advancements. As a result, consumers now have a way to better diagnose diseases at an early stage and pay less overall for more invasive routine diagnostic services. Additionally, a smart implantable is another wearable device that will use artificial intelligence for sensors to monitor blood pressure, heart rate, glucose level, etc. For instance, Proteus, a bioscience company, produced a digital pill, which allows consumers to understand body metrics, as after swallowing the pill, the consumers get their body metrics using an external device.

There are various technological advancements taking place in the market. Some of them include the adoption of 5G, biosensors, beacon technology, smart rings, smart implantable, etc. Moreover, many device manufacturers are focusing on incorporating wellness and personal health features in the wearables such as blood oxygen sensors, heart rate monitors, electrocardiogram monitors, and other sensors that alert potential health issues. For instance, Fitbit offers watches with built-in thermometers that alert people regarding potential fever, especially during the COVID-19 pandemic.

E-payments through wearables are another trend that is driving the market. For instance, Lyle & Scott, a British menswear designer, collaborated with Barclaycard to launch a contactless payment jacket with a chip-in cuff that allowed conducting contactless payment. For instance, in October 2015, Ringly, in collaboration with Mastercard, allowed customers to make contactless payments by wearing their rings. In May 2022, Sony introduced Wena 3, a smartwatch that can be used as a regular watch but it accepts mobile payments via Barclaycard in the U.K. bPay, a wearable technology company, backed by Barclaycard, offers jackets, fobs, and stickers that can be used to perform contactless payments.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

• The global cancer registry software market size was valued at USD 75.8 million in 2023 and is projected to grow at a CAGR of 12.7% from 2024 to 2030. The increasing incidence of cancer and a growing number of accountable care organizations are among the factors driving the market growth.

• The global point of care connectivity solutions market was estimated at USD 1.02 billion in 2023 and is projected to grow at a CAGR of 7.40% from 2024 to 2030. The market growth is driven by several factors, including the growing need for real-time data integration from medical devices to electronic health records (EHRs), which enhances patient care and decision-making.

Wearable AI Market Segmentation

Grand View Research has segmented the global wearable AI market based on type, application, operations, component, and region:

Wearable AI Type Outlook (Revenue, USD Million, 2017 - 2030)
• Smartwatches
• Smart Eyewear
• Smart Earwear
• Others

Wearable AI Application Outlook (Revenue, USD Million, 2017 - 2030)
• Consumer Electronics
• Healthcare
• Automotive
• Military & Defense
• Media & Entertainment
• Others

Wearable AI Operations Outlook (Revenue, USD Million, 2017 - 2030)
• On-device AI
• Cloud-based AI

Wearable AI Component Outlook (Revenue, USD Million, 2017 - 2030)
• Processor
• Connectivity IC
• Sensors

Wearable AI Regional Outlook (Revenue, USD Million, 2017 - 2030)
• North America
o U.S.
o Canada
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Singapore
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE

Order a free sample PDF of the Wearable AI Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• Amazon.com, Inc.
• Fitbit, Inc.
• Garmin Ltd.
• Google, Inc.
• Huawei Technologies Co. Ltd.
• IBM
• Motorola Solutions, Inc.
• TomTom International B.V.
• Apple, Inc.
• Samsung Electronics Co. Ltd.
• Sony Corporation

Attention Deficit Hyperactivity Disorder Market - Emerging Trends And The Role Of Regulatory Frameworks

 Attention Deficit Hyperactivity Disorder Industry Overview

The global attention deficit hyperactivity disorder market size was estimated at USD 14.3 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2030. The market's growth can be attributed to the escalating demand for attention deficit hyperactivity disorder (ADHD) drugs, driven by the rising global prevalence of ADHD. This growth is further fueled by the increasing awareness about the disorder among healthcare professionals and patients, as well as the escalating healthcare expenditure across various regions.

Gather more insights about the market drivers, restrains and growth of the Attention Deficit Hyperactivity Disorder Market

The prevalence of ADHD in children has been linked to reduced health and well-being for patients and their families. As a common neurological developmental disorder, ADHD is increasingly recognized in adolescents, adults, and children. According to a study published in the Italian Journal of Pediatrics in 2023, the global prevalence of ADHD in children aged 3 to 12 years is 7.6%, while it is 5.6% for those aged 12 to 18 years. The Forbes Health Report of 2023 indicates that approximately 129 million adolescents and children between 5 to 19 years old are living with ADHD. Consequently, the rising prevalence of ADHD is expected to drive the demand for medications used in its treatment.

The growing awareness of ADHD among patients, healthcare professionals, and other medical practitioners is expected to stimulate the diagnosis and treatment of the condition, propelling market growth. Enhanced understanding of ADHD is expected to contribute to improved academic outcomes for students affected by the disorder. In an effort to advance treatment quality for children with ADHD, the National Institute for Children's Health Quality has implemented a collaborative model in partnership with children and adults with Attention-Deficit/Hyperactivity Disorder (CHADD) and the American Academy of Pediatrics (AAP).

In addition to the efforts of the National Institute for Children's Health Quality, organizations such as the ADHD Coaches Organization (ACO), Attention Deficit Disorder Association (ADDA), and CHADD are proactively working to raise awareness about ADHD and available treatment options globally through various campaigns. For instance, in 2022, these organizations organized a program called "Reframing ADHD: Discovering New Perspectives," that aimed to address aspects including ADHD relationships and communications, diagnosis in children and adults, treatment plans, and co-occurring situations.

October is recognized worldwide as ADHD Awareness Month, dedicated to increasing understanding and educating people about ADHD. According to CHADD, the healthcare costs associated with treating ADHD in adults aged 18 to 64 range from USD 137 to USD 4,100 per person annually. Consequently, the growing financial burden has led to a heightened need for evaluating efficient, low-cost treatment options for ADHD that significantly contribute to market growth.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global pharmerging market size was valued at USD 1.73 trillion in 2023 and is projected to grow at a CAGR of 2.6% from 2024 to 2030. This growth is attributed to the growing requirement for affordable generics.

• The global doxorubicin market size was valued at USD 989.6 million in 2023 and is projected to grow at a CAGR of 6.6% from 2024 to 2030. Doxorubicin, a potent chemotherapy drug in the anthracycline class, has established a significant presence in the global pharmaceutical market.

Attention Deficit Hyperactivity Disorder Market Segmentation

Grand View Research has segmented the global attention deficit hyperactivity disorder market based on drug type, demographics, distribution channel, and region:

Attention Deficit Hyperactivity Disorder Drug Type Outlook (Revenue, USD Million, 2018 - 2030)
• Stimulants
o Amphetamine
o Methylphenidate
o Lisdexamfetamine
o Dexmethylphenidate
• Non-stimulants
o Atomoxetine
o Guanfacine
o Clonidine
o Others

Attention Deficit Hyperactivity Disorder Demographics Outlook (Revenue, USD Million, 2018 - 2030)
• Children
• Adults

Attention Deficit Hyperactivity Disorder Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Retail Pharmacy
• Hospital Pharmacy

Attention Deficit Hyperactivity Disorder Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Order a free sample PDF of the Attention Deficit Hyperactivity Disorder Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• Eli Lilly and Company.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt Inc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceutical, Inc.

Key Attention Deficit Hyperactivity Disorder Company Insights

• Novartis AG, a global pharmaceutical company, offers various brands for the treatment of attention deficit hyperactivity disorder. Some of the notable Novartis AG brands for ADHD include Ritalin, Concerta, Adderall, Vyvanse, and Strattera.

• Eli Lilly and Company, a multinational pharmaceutical corporation, also offers a variety of brands for the management of attention deficit hyperactivity disorder. The Eli Lilly and Company brands for ADHD include Adderall XR and QuilliChew ER.

Recent Developments

• In July 2022, Swedish pharmaceutical company AGB-Pharma introduced Adaflex, the first melatonin product in the UK designed for insomnia in children and adolescents aged 6 to 17 years with ADHD when conventional sleep hygiene measures prove insufficient.

• In April 2022, Supernus Pharmaceuticals, Inc. received FDA approval for Qelbree, developed by Supernus Pharmaceuticals, Inc., for treating ADHD patients aged 18 years and above. This approval was anticipated to increase the consumer base for the product.